The all-cash deal adds divesiran, a late-stage-ready rare-disease therapy, to Merck KGaA's pipeline and signals a new wave of RNA therapeutics M&A.

Pioneer Labs CEO Erika DeBenedictis is engineering microbes to terraform Mars, turning a sci-fi dream into a biotech business model.

The imaging giant's pivot into drug manufacturing was supposed to write its second act. Investors are still waiting on returns.